OVIT (OncoVista Innovative Therapies) Return-on-Tangible-Asset: -2,930.34% (As of Sep. 2015)


What is OncoVista Innovative Therapies Return-on-Tangible-Asset?

OncoVista Innovative Therapies OVIT Return-on-Tangible-Asset is -2,930.34% as of Sep. 2015.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. OncoVista Innovative Therapies's annualized Net Income for the quarter that ended in Sep. 2015 was $-1.30 Mil. OncoVista Innovative Therapies's average total tangible assets for the quarter that ended in Sep. 2015 was $0.04 Mil. Therefore, OncoVista Innovative Therapies's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2015 was -2,930.34%.

The historical rank and industry rank for OncoVista Innovative Therapies's Return-on-Tangible-Asset or its related term are showing as below:

OVIT's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -35.77
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

OncoVista Innovative Therapies  (OTCPK:OVIT) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


OncoVista Innovative Therapies Return-on-Tangible-Asset Related Terms


OncoVista Innovative Therapies Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for OncoVista Innovative Therapies's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies Return-on-Tangible-Asset Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 510.25 -70.57 -117.87 -432.19 -4,667.89

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 829.22 -9,521.21 -3,211.59 -10,438.10 -2,930.34

OVIT vs RSPI, HSTC, CAPS: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, OncoVista Innovative Therapies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoVista Innovative Therapies Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's Return-on-Tangible-Asset falls into.



OncoVista Innovative Therapies Return-on-Tangible-Asset Calculation

OncoVista Innovative Therapies's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2014 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2014 )  (A: Dec. 2013 )(A: Dec. 2014 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2014 )  (A: Dec. 2013 )(A: Dec. 2014 )
=-2.544/( (0.096+0.013)/ 2 )
=-2.544/0.0545
=-4,667.89 %

OncoVista Innovative Therapies's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2015 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2015 )  (Q: Jun. 2015 )(Q: Sep. 2015 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2015 )  (Q: Jun. 2015 )(Q: Sep. 2015 )
=-1.304/( (0.028+0.061)/ 2 )
=-1.304/0.0445
=-2,930.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2015) net income data.

What does a Return-on-Tangible-Asset of -2,930.34% mean?
OncoVista Innovative Therapies (OVIT) has a Return-on-Tangible-Asset of -2,930.34% as of Sep. 2015. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on OncoVista Innovative Therapies and its competitors.
Is OncoVista Innovative Therapies' Return-on-Tangible-Asset too high?
OncoVista Innovative Therapies' current Return-on-Tangible-Asset is -2,930.34%.
How does OncoVista Innovative Therapies' Return-on-Tangible-Asset compare to RSPI and HSTC?
OncoVista Innovative Therapies' Return-on-Tangible-Asset of -2,930.34% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on OncoVista Innovative Therapies and its competitors. OncoVista Innovative Therapies's current Return-on-Tangible-Asset is -2,930.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoVista Innovative Therapies stock overvalued right now?
OncoVista Innovative Therapies (OVIT) has a current Return-on-Tangible-Asset of -2,930.34%. The current Return-on-Tangible-Asset is -2,930.34%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For OncoVista Innovative Therapies (OVIT), the current Return-on-Tangible-Asset is -2,930.34% as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoVista Innovative Therapies Business Description

Address 14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.